{"schema_version":"secwatch.filing_event.v1","accession":"0000785557-22-000013","form_type":"8-K","ticker":"DLHC","cik":"0000785557","company_name":"DLH Holdings Corp.","filed_at":"2022-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.145931+00:00","generated_at":"2026-06-24T06:10:07.820954+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DLH Q3 revenue $66.4M (+8% YoY), EPS $0.34, operating margin 10.7%","bullets":["Revenue $66.4M, up 8% YoY; net income $4.9M vs $2.9M; diluted EPS $0.34 vs $0.21.","Operating margin improved to 10.7% from 8.0% on higher revenue, better mix, and lower fringe costs.","Debt reduced to $28.5M from $37.5M at March 31, 2022; total backlog $509.7M.","Won DoD health R&D IDIQ and NIH National Cancer Institute clinical research contract.","EBITDA $9.0M (13.5% of revenue) vs $7.0M (11.3%) in prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0000785557-22-000013","json":"https://secwatch.observer/filing/0000785557-22-000013.json","markdown":"https://secwatch.observer/filing/0000785557-22-000013.md","text":"https://secwatch.observer/filing/0000785557-22-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/785557/000078555722000013/0000785557-22-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/785557/000078555722000013/dlhc-20220802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:10:07.820954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}